Seelos Therapeutics Inc
NASDAQ:SEEL
Seelos Therapeutics Inc
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 15 full-time employees. The firm is focused on the development of products that address unmet needs in central nervous system (CNS) disorders and other rare disorders. The firm's lead programs SLS-002 for the treatment of acute suicidal ideation and behavior (ASIB) in depressive disorder (MDD), and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS). SLS-005 for the potential treatment of Sanfilippo Syndromes, which is being explored. The company is also developing several preclinical programs, including SLS-010, an oral histamine H3A receptor antagonist that shows promising activity in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management. The firm's ongoing programs include SLS-004, SLS-006, SLS-007 and SLS-008.
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 15 full-time employees. The firm is focused on the development of products that address unmet needs in central nervous system (CNS) disorders and other rare disorders. The firm's lead programs SLS-002 for the treatment of acute suicidal ideation and behavior (ASIB) in depressive disorder (MDD), and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS). SLS-005 for the potential treatment of Sanfilippo Syndromes, which is being explored. The company is also developing several preclinical programs, including SLS-010, an oral histamine H3A receptor antagonist that shows promising activity in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management. The firm's ongoing programs include SLS-004, SLS-006, SLS-007 and SLS-008.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
